Evidence map›Paper›PMID 34526300›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2021

Lung Cancer as a Subsequent Malignant Neoplasm in Survivors of Childhood Cancer.

Taumoha Ghosh, Yan Chen, Andrew C Dietz, Gregory T Armstrong, Rebecca M Howell, Susan A Smith, Daniel A Mulrooney, Lucie M Turcotte, Yan Yuan, Yutaka Yasui and 1 more

Open access · bronzeAbstract readComment
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Secondary Lung Cancer among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Taumoha GhoshUniversity of Miami, Miami, Florida. tghosh@med.miami.edu.ORCID 0000-0003-3420-3167
Yan ChenUniversity of Alberta, Edmonton, Alberta, Canada.
Andrew C DietzBluebird bio, Inc., Cambridge, Massachusetts.
Gregory T ArmstrongSt. Jude Children's Research Hospital, Memphis, Tennessee.
Rebecca M HowellThe University of Texas MD Anderson Cancer Center, Houston, Texas.
Susan A SmithThe University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-6367-3080
Daniel A MulrooneySt. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0003-2351-9115
Lucie M TurcotteUniversity of Minnesota, Minneapolis, Minnesota.ORCID 0000-0003-4106-6172
Yan YuanUniversity of Alberta, Edmonton, Alberta, Canada.
Yutaka YasuiSt. Jude Children's Research Hospital, Memphis, Tennessee.
Joseph P NegliaUniversity of Minnesota, Minneapolis, Minnesota.
St. Jude Children's Research Hospital · USThe University of Texas MD Anderson Cancer Center · USUniversity of Alberta · CAUniversity of Minnesota · USBluebird Bio (United States) · USUniversity of Miami · US

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Shondra Michelle Miller · 1985 to 2026
$166.9M
Mach-LETSGO: Machine-LEarning of Treatment, Survey, and Genetics towards Obtaining Correct Classification of Chronic Conditions in Adult Survivors in the Childhood Cancer Survivor Study - CCSS SupplU24CA055727 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Gregory Armstrong · 1999 to 2026
$96.7M
Translational Pediatric Cancer Epidemiology Research Training GrantT32CA099936 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Logan G. Spector · 2004 to 2026
$5.1M
Treatment Modifications, Outcomes and Provider Decision Making in the Management of Subsequent Breast Cancers Among Survivors of Childhood CancerK08CA234232 · NCI · UNIVERSITY OF MINNESOTA · PI TURCOTTE, LUCIE MARIE · 2018 to 2021
$714k
NCI NIH HHS K08 CA234232NCI NIH HHS P30 CA021765NCI NIH HHS T32 CA099936NCI NIH HHS U24 CA055727
6 · The paper itself

Abstract

backgroundLung cancer, the most common cause of cancer-related death in adults, has not been well studied as a subsequent malignant neoplasm (SMN) in childhood cancer survivors. We assessed prevalence, risk factors, and outcomes for lung SMN in the Childhood Cancer Survivor Study (CCSS) cohort.

methodsAmong 25,654 5-year survivors diagnosed with childhood cancer (<21 years), lung cancer was self-reported and confirmed by pathology record review. Standardized incidence ratios (SIR) and cumulative incidences were calculated, comparing survivors to the general population, and hazard ratios (HR) were estimated using Cox regression for diagnosis and treatment exposures.

resultsForty-two survivors developed a lung SMN [SIR, 4.0; 95% confidence interval (CI), 2.9-5.4] with a cumulative incidence of 0.16% at 30 years from diagnosis (95% CI, 0.09%-0.23%). In a treatment model, chest radiation doses of 10-30 Gy (HR, 3.4; 95% CI, 1.05-11.0), >30-40 Gy (HR, 4.6; 95% CI, 1.5-14.3), and >40 Gy (HR, 9.1; 95% CI, 3.1-27.0) were associated with lung SMN, with a monotone dose trend (

conclusionsSurvivors of childhood cancer are at increased risk for lung cancer compared with the general population. Greatest risk was observed among survivors who received chest radiotherapy or with primary diagnoses of Hodgkin lymphoma or bone cancer. IMPACT: This study describes the largest number of observed lung cancers in childhood cancer survivors and elucidates need for further study in this aging and growing population.

Indexed as

Cancer SurvivorsLung NeoplasmsAdultChildHumansIncidenceRisk FactorsSurvivors

Identifiers

PMID34526300
PMCPMC8643305
OpenAlexW3200961293

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.